Sign In
Search Icon
Menu Icon

Important Update

HHS Announces State/territory-coordinated Distribution System for Monoclonal Antibody Therapeutics

September 13, 2021

Monoclonal Antibody Therapeutic Updates

The COVID-19 pandemic is rapidly evolving, and new updates are issued frequently. To view a full list of HHS/ASPR’s updates related to COVID-19 monoclonal antibody therapeutics, please see our full list of updates.

The increased incidence of the Delta variant of SARS-CoV-2 has caused a substantial surge in the utilization of monoclonal antibody (mAb) drugs, particularly in areas of the country with low vaccination rates. HHS is committed to helping ensure consistent availability of these critical drugs for current and future patients in all geographic areas of the country. As such, we have updated the distribution process for mAbs.

On Monday, September 13, HHS transitioned from a direct ordering process to a state/territory-coordinated distribution system similar to that used for the distribution of mAbs from November 2020 – February 2021.

State and territorial health departments know best where product is needed in their areas. Transitioning to a state/territory-coordinated distribution system gives health departments maximum flexibility to get these critical drugs where they are needed most.

HHS will determine the weekly amount of mAb products each state and territory receives based on COVID-19 case burden and mAb utilization. State and territorial health departments will subsequently identify which sites in their respective jurisdictions receive product as well as the amount each site receives.

As of Monday, September 13, 2021:

  • Administration sites no longer order directly from AmerisourceBergen.
  • Weekly distribution amounts for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations in addition to data on inventories and use submitted to the federal government.
  • State/Territorial Health Departments will determine where product goes in their jurisdictions.

State/Territory Distributions for Week of September 13, 2021

HHS will continue to monitor product utilization rates, COVID-19 case burden, and overall availability of monoclonal antibody therapeutics to determine when a shift back to the normal direct ordering process may be possible.

State/Territory Name Bamlanivimab/etesevimab Doses REGN-COV Doses
Alaska 60 470
Alabama 810 7,220
Arkansas 370 3,260
American Samoa 0 20
Arizona 180 1,620
California 520 4,610
Colorado 100 860
Connecticut 40 290
District of Columbia 30 180
Delaware 20 180
Florida 3,100 27,850
Georgia 1,000 8,920
Guam 0 120
Hawaii 70 610
Iowa 140 1,190
Idaho 110 970
Illinois 280 2,490
Indiana 310 2,710
Kansas 110 940
Kentucky 500 4,460
Louisiana 850 7,650
Massachusetts 70 570
Maryland 110 910
Maine 30 270
Michigan 190 1,690
Minnesota 130 1,090
Missouri 230 1,990
Commonwealth of the Northern Mariana Islands 0 10
Mississippi 960 8,550
Montana 80 720
North Carolina 650 5,850
North Dakota 40 340
Nebraska 80 680
New Hampshire 40 330
New Jersey 230 1,980
New Mexico 80 650
Nevada 100 820
New York 490 4,410
Ohio 370 3,250
Oklahoma 320 2,840
Oregon 140 1,240
Pennsylvania 220 1,970
Puerto Rico 40 270
Rhode Island 30 250
South Carolina 450 4,010
South Dakota 50 380
Tennessee 780 6,940
Texas 2,370 21,270
Utah 140 1,190
Virginia 160 1,370
Virgin Islands 0 30
Vermont 20 120
Washington 130 1,160
Wisconsin 140 1,210
West Virginia 160 1,440
Wyoming 50 360
Indian Health Service 100 900
Veteran's Health Administration 100 900
Totals 17,880 158,580

​​